Grace Therapeutics, Inc.
-42.6% · 90d
$2.16
-0.14 (-6.09%)
After-Hours $2.18(+0.02)
News
(1)April 2026
GRCE Receives FDA Complete Response Letter for GTx-104
GRCEGrace Therapeutics, Inc.
# 📄 What This Document Is This is an 8-K filing, which companies use to announce major news to investors. Here, Grace Therapeutics is sharing that the FDA rejected their initial application for a new drug called GTx-104. It’s not a final "no," but a "not yet" — a Complete Response Letter (CRL) sayi
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%